Key result
Strong correlation between BNP and NT-proBNP enables a conversion formula for AL amyloidosis staging.
Why the study?
Cardiac involvement determines prognosis in light-chain amyloidosis, and BNP and NT-proBNP are central for diagnosis and risk stratification.
Can a conversion formula reliably convert NT-proBNP to BNP values for cardiac staging in patients with light-chain (AL) amyloidosis?
Observational (n=353)
Yes
Can a conversion formula reliably convert NT-proBNP to BNP values for cardiac staging in patients with light-chain (AL) amyloidosis?
Effect estimate: R2 = 0.815
A novel disease-specific formula accurately converts NT-proBNP to BNP in AL amyloidosis, facilitating harmonized cardiac staging and longitudinal assessment across different assays.
May enable assay-agnostic cardiac staging in AL amyloidosis; leaves open prospective validation before clinical adoption.
ardiac involvement is the principal determinant of prognosis in light-chain (AL) amyloidosis. B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are central for diagnosis, risk stratification
No takes yet. Share an insight, caveat, or question.
Muchtar et al. (2026) conducted an observational in Light-chain (AL) amyloidosis (n=353). Paired BNP and NT-proBNP biomarker assessment was evaluated on Linear association between log-transformed BNP and NT-proBNP values (R2 = 0.815). A strong linear association was observed between log-transformed BNP and NT-proBNP (R2 = 0.815), allowing the derivation of a conversion formula to harmonize cardiac staging in AL amyloidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: